Preexisting MEK1 Exon 3 Mutations in (V600E/K)BRAF Melanomas Do Not Confer Resistance to BRAF Inhibitors

BRAF inhibitors (BRAFi) induce antitumor responses in nearly 60% of patients with advanced (V600E/K)BRAF melanomas. Somatic activating MEK1 mutations are thought to be rare in melanomas, but their potential concurrence with (V600E/K)BRAF may be selected for by BRAFi. We sequenced MEK1/2 exon 3 in me...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Shi, Hubing, Moriceau, Gatien, Kong, Xiangju, Koya, Richard C., Nazarian, Ramin, Pupo, Gulietta M., Bacchiocchi, Antonella, Dahlman, Kimberly B., Chmielowski, Bartosz, Sosman, Jeffrey A., Halaban, Ruth, Kefford, Richard F., Long, Georgina V., Ribas, Antoni, Lo, Roger S.
Formato: Artigo
Idioma:Inglês
Publicado em: 2012
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3594852/
https://ncbi.nlm.nih.gov/pubmed/22588879
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-12-0022
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados